The Pharma Data

MARCH 9, 2021

Lilly will present detailed results of the TRAILBLAZER-ALZ phase 2 study, which showed that donanemab treatment resulted in significant slowing of decline in a composite measure of cognition and daily function in people with early symptomatic Alzheimer’s disease (AD) compared to placebo. . Mevidalen/D1PAMs.

Disease 40

Disease International Research Therapies 40

The Pharma Data

AUGUST 5, 2021

approval; acquisition of Vividion Therapeutics agreed; start of first clinical study for Parkinson’s cell therapy treatment. Food and Drug Administration for the treatment of adult patients with chronic kidney disease and type 2 diabetes. Group sales increase by 12.9 percent (Fx & portfolio adj.) percent to 1.61

Production 52

Production Pharmaceuticals Science Therapies 52

Drug Discovery World

APRIL 10, 2024

With this heightened interest, insight into the current state of obesity research and its future direction is particularly valuable. An ICON survey of over 100 drug development professionals in obesity research revealed optimism about future therapies, with a significant shift towards combination treatments for obesity and its comorbidities.

Clinical Trials 130

Clinical Trials Trials Therapies Treatment 130

Drug Discovery World

MAY 30, 2023

We believe one of the most exciting developments that has high potential to make a significant difference to treating cancer is the novel treatment option to TNBC patients called Immunopheresis. We are even more excited about what the next five years will bring by way of new treatment options for cancer patients.”

Research 130

Research Targeted Protein Degradation Drugs RNA 130

Drug Discovery World

JUNE 26, 2023

Now, there are many mRNA-based therapeutics in clinical development and mRNA cancer vaccines have been promised by 2030. Although the concept of using mRNA to make therapeutics or vaccines has been around for decades, it took the urgency of a global pandemic for it to become a reality.

Vaccine 130

Vaccine Virus Clinical Trials Trials 130

Drug Discovery World

FEBRUARY 15, 2023

Another revolutionary discovery was the elucidation of the role of IL2 in T cell growth and activation in the 1970s, that later paved the way for the treatment of patients with metastatic melanoma and renal cancer. Over 250 clinical trials are currently in progress, and novel immuno-oncological treatments are already proving to be successful.

Research 130

Research Therapies Immune Response Clinical Trials 130

The Pharma Data

NOVEMBER 5, 2020

Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” Updates from the clinical pipeline include: Dupixent ® (dupilumab). Business Highlights. Oncology Program.

Production 52

Production FDA FDA Approval Trials 52

The Pharma Data

FEBRUARY 24, 2022

with more than 8 million cases expected by 2030. with preserved ejection fraction, a form of heart failure that has very limited treatment options.” vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc.

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

Drug Discovery World

NOVEMBER 18, 2022

World Antimicrobial Awareness Week highlights the fact that antimicrobials have formed the bedrock of modern medicine, making surgeries, cancer care and treatments for life-threatening infections possible and improving human health in the process. . References . 1: Global Database for Tracking Antimicrobial Resistance (AMR). 2: [link] .

Pharmaceutical Companies 130

Pharmaceutical Companies Government Pharmaceuticals Hospitals 130

PerkinElmer

JANUARY 25, 2023

To help make more timely and informed clinical candidate decisions going forward, scientists need to be able to securely, intuitively, and quickly find, analyze and share critical discovery-stage data, as well as do reliable predictive analysis. These same challenges and needs also extend from research and discovery to clinical development.

Science 52

Science Laboratories Immune Response Disease 52